<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313247</url>
  </required_header>
  <id_info>
    <org_study_id>Par 06-0045</org_study_id>
    <nct_id>NCT01313247</nct_id>
  </id_info>
  <brief_title>Paracetamol for Cancer Pain</brief_title>
  <official_title>Optimizing Medication for Cancer Pain. The Effect of Paracetamol. A Clinical and Pharmacological Trial to Research Whether Paracetamol Gives an Additional Effect on Pain Relief When the Patient is Treated With High Doses of Opioids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haraldsplass Deaconess Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haraldsplass Deaconess Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, double-blind placebo controlled cross-over trial

      Main goal:

      Optimize the medical pain treatment for patients with advanced cancer disease

      Study goal:

      Measure paracetamol's additional analgesic effect in a situation where the patient is
      concomitantly treated with oral opioids eqv. morphine &gt; 100 mg/d.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      National multicenter study with an intention to include 50 patients. 6 days treatment, 3d in
      each arm. Mean pain score last 24 h: NRS =/&gt; 4 All drug treatment constant during the study
      period. The participants are allowed to take as much rescue opioids as necessary to have
      adequate relief.

      Paracetamol/ placebo given orally 1000 mg x 4 daily, three days in each arm, direct
      crossover.

      Daily scoring of pain relief, ESAS, overall satisfaction and rescue medication.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction caused by paracetamol 4g/d</measure>
    <time_frame>Last day in each 3 days study period</time_frame>
    <description>Pain reduction in the active paracetamol arm, compared to placebo, corrected for difference in rescue medication intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction with the pain treatment</measure>
    <time_frame>End of each 3 days study period</time_frame>
    <description>Total ESAS score Sweating during nighttime general wellbeing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Opioid Use, Unspecified</condition>
  <arm_group>
    <arm_group_label>Placebo pills</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral paracetamol 4 g daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>1000 mg 4 times daily</description>
    <arm_group_label>oral paracetamol 4 g daily</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo tablets</intervention_name>
    <description>Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol</description>
    <arm_group_label>Placebo pills</arm_group_label>
    <other_name>Suger pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (&gt; 18 years) of both sexes

          -  Diagnosed with advanced cancer disease

          -  Ongoing medicinal pain relief treatment in stable dosing with oral opiates equivalent
             to &gt; 100 mg oral morphine daily

          -  NRS median pain score last 24 hrs &gt; 4

          -  Able to take tablets (paracetamol) orally

        Exclusion Criteria:

          -  Mental or physical deficiency precluding data collection.

          -  Reduced liver function judged with bilirubin, INR and transaminases

          -  Anticoagulation with warfarin

          -  Ongoing use of NSAIDs or 5-HT3 antagonists, or use of such drugs last week

          -  Ongoing palliative radiation treatment or radiation treatment during the last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Henrik Rosland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haraldsplass Deaconess Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Henrik Rosland, MD, PhD</last_name>
    <phone>+4755979400</phone>
    <phone_ext>79387</phone_ext>
    <email>jhro@haraldsplass.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sindre Hoel, MD</last_name>
    <phone>+4755975000</phone>
    <email>sindre.hoel@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haraldsplass Deaconess Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5009</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sindre Hoel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <last_update_submitted>March 10, 2011</last_update_submitted>
  <last_update_submitted_qc>March 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jan Henrik Rosland, professor</name_title>
    <organization>Haraldsplass Deaconess Hospital</organization>
  </responsible_party>
  <keyword>Paracetamol</keyword>
  <keyword>opioids</keyword>
  <keyword>cancer pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

